Factor VII Levels and International Normalized Ratios in the Early Phase of Warfarin Therapy

被引:27
作者
Benzon, Honorio T. [1 ]
Avram, Michael J. [1 ]
Benzon, Hubert A. [1 ]
Kirby-Nolan, Misty [1 ]
Nader, Antoun [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA
关键词
LOW-DOSE WARFARIN; BREAST-CANCER; PROTEIN-S; FACTOR-II; FACTOR-X; FACTOR-IX; INITIATION; PLASMA; AGE; ANTICOAGULATION;
D O I
10.1097/ALN.0b013e3181ca6cfc
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Factor VII is the most affected clotting factor during the early phase of warfarin therapy. An international normalized ratio (INR) of more than 1.4 is considered unsafe for epidural catheter placement or removal, according to the American Society of Regional Anesthesia and Pain Medicine. The authors tested the hypothesis that factor VII activities would be consistent with safe removal of the epidural catheter on postoperative day (POD) 1 regardless of INR value. Methods: Data from 121 patients who took warfarin after undergoing total joint surgery and had INRs and factor VII levels determined were reviewed. Patient characteristics and factor VII activities were compared between patients with INRs of more than 1.4 and those with INRs less than or equal to 1.4 on PODS 1, 2, and 3. Results: Eleven patients had INRs of more than 1.4 on POD 1; their mean +/- SD factor VII activities were 60 +/- 28% (normal: 50-160%). On POD 2, 78 patients with INRs more than of 1.4 had factor VII activities of 32 +/- 15%, whereas on POD 3, 84 patients with INRs of more than 1.4 had factor VI I activities of 44 +/- 19%. Variables included in the final multiple logistic regression model as predictors of an INR of more than 1.4 on POD 2 were warfarin dose on POD 1 and factor VII activity on POD 2. Conclusions: The range of factor VII activities in the patients with INRs of more than 1.4 within 12 h of warfarin therapy was compatible with adequate hemostasis. The authors found no evidence that epidural catheters should not be removed even with INRs up to 1.9, the highest INR on POD 1 noted in their study.
引用
收藏
页码:298 / 304
页数:7
相关论文
共 23 条
[1]   MECHANISM OF WARFARIN POTENTIATION BY AMIODARONE - DOSE-DEPENDENT AND CONCENTRATION-DEPENDENT INHIBITION OF WARFARIN ELIMINATION [J].
ALMOG, S ;
SHAFRAN, N ;
HALKIN, H ;
WEISS, P ;
FARFEL, Z ;
MARTINOWITZ, U ;
BANK, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (03) :257-261
[2]  
[Anonymous], 2002, American Journal of Kidney Diseases, V39, pS46
[3]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[4]  
Falanga A, 1998, THROMB HAEMOSTASIS, V79, P23
[5]   Oral anticoagulants in the elderly [J].
Froom, P ;
Miron, E ;
Barak, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) :526-528
[6]  
GANEVAL D, 1986, CLIN NEPHROL, V25, P75
[7]  
Goudie BM, 2004, BRIT J GEN PRACT, V54, P690
[8]   Clinically important drug interactions with anticoagulants - An update [J].
Harder, S ;
Thurmann, P .
CLINICAL PHARMACOKINETICS, 1996, 30 (06) :416-444
[9]   Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy [J].
Harrison, L ;
Johnston, M ;
Massicotte, MP ;
Crowther, M ;
Moffat, K ;
Hirsh, J .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (02) :133-136
[10]   Changes in levels of factor VII and protein S after acute myocardial infarction: Effects of low-dose warfarin [J].
Holm, J ;
Hillarp, A ;
Erhardt, L ;
Berntorp, E .
THROMBOSIS RESEARCH, 1999, 96 (03) :205-212